Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.

Autor: How J; Division of Hematology Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA., Ren S; Department of Data Sciences Dana-Farber Cancer Institute Boston Massachusetts USA., Lombardi-Story J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Bergeron M; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Foster J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Amrein PC; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Brunner AM; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Fathi AT; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Hock H; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Khachatryan A; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Kikuchi H; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Ng MR; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Moran J; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Narayan R; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Neuberg D; Department of Data Sciences Dana-Farber Cancer Institute Boston Massachusetts USA., Ramos A; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Som T; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Vartanian M; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Chen YB; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Duda DG; Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA., Hobbs GS; Department of Medical Oncology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.

Publikováno v: EJHaem [EJHaem] 2022 Mar 06; Vol. 3 (2), pp. 434-442. Date of Electronic Publication: 2022 Mar 06 (Print Publication: 2022).